GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Renalytix PLC (LSE:RENX) » Definitions » Float Percentage Of Total Shares Outstanding

Renalytix (LSE:RENX) Float Percentage Of Total Shares Outstanding : 0.00% (As of May. 25, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Renalytix Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Renalytix's float shares is 0.00 Mil. Renalytix's total shares outstanding is 154.37 Mil. Renalytix's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Renalytix's Insider Ownership is 16.92%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Renalytix's Institutional Ownership is 10.10%.


Renalytix Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Renalytix's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/154.37
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Renalytix (LSE:RENX) Business Description

Industry
Traded in Other Exchanges
Address
5-7 Cranwood Street, Finsgate, London, GBR, EC1V 9EE
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

Renalytix (LSE:RENX) Headlines

From GuruFocus

Causeway International's Top Five Holdings

By Monica Wolfe Monica Wolfe 08-29-2013

Investing in Information

By Vanina Egea Vanina Egea 03-06-2014

Paul Singer Buys Reed Elesvier

By matsandalex matsandalex 12-14-2012